Related Experiment Video
Updated: Aug 9, 2026

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
Published on: September 23, 2015
Differential effects of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on BDNF mRNA expression in rat frontal
Rebeca Martínez-Turrillas1, Sonia Moyano, Joaquín Del Río
1Department of Pharmacology, School of Medicine, University of Navarra, Aptdo. 177, 31080-Pamplona, Spain.
Abstract:
The serotonergic neurotoxin 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") produces rapid serotonin (5-HT) depletion in different areas of the forebrain after acute administration to rats and other animal species. We previously found that 5-HT depletion induced by acute MDMA treatment was transient in the frontal cortex, but not in the hippocampus, and recovery of cortical 5-HT levels correlated with an induction of CRE-binding activity and increased expression of tryptophan-hydroxylase (TPH), the rate-limiting enzyme in 5-HT biosynthesis. As the brain-derived neurotrophic factor (BDNF) stimulates the growth and sprouting of serotonergic neurons, we sought the possible involvement of this neurotrophin in the region-specific increase in TPH mRNA expression induced by MDMA. We here report that, 24-48 h after acute MDMA treatment, the expression of BDNF in the frontal cortex is increased by approximately 33-70%, and the levels of the transcription factor phospho-CREB are also increased. In the hippocampus, however, a time-dependent decrease in BDNF mRNA expression (maximal decrease of approximately 73%) is found in all subfields examined 2-7 days after treatment in spite of increased phospho-CREB levels, perhaps as a consequence of corticosterone release by the serotonergic neurotoxin. The differential regulation of BDNF mRNA expression in the two brain regions examined appears to account for the enhanced TPH expression and the recovery of 5-HT levels in the frontal cortex, but not in the hippocampus, after neurotoxin treatment.
Insights
3,4-methylenedioxymethamphetamine (MDMA) affects serotonin (5-HT) levels differently in rat brain regions. MDMA increases brain-derived neurotrophic factor (BDNF) in the frontal cortex, aiding 5-HT recovery, but decreases it in the hippocampus.
Area of Science:
- Neuroscience
- Neuropharmacology
- Molecular Biology
Background:
- 3,4-methylenedioxymethamphetamine (MDMA) is a neurotoxin that depletes serotonin (5-HT) in the brain.
- MDMA-induced 5-HT depletion is transient in the frontal cortex but persistent in the hippocampus.
- Recovery of 5-HT in the frontal cortex correlates with increased tryptophan hydroxylase (TPH) expression.
Purpose of the Study:
- To investigate the role of brain-derived neurotrophic factor (BDNF) in the region-specific regulation of TPH mRNA expression following MDMA treatment.
- To understand the differential recovery of serotonin levels in the frontal cortex and hippocampus after MDMA exposure.
Main Methods:
- Acute administration of MDMA to rats.
- Measurement of BDNF mRNA expression in the frontal cortex and hippocampus at various time points post-treatment.
- Analysis of phospho-CREB levels and TPH mRNA expression.
Main Results:
- MDMA treatment increased BDNF mRNA expression (33-70%) and phospho-CREB levels in the frontal cortex within 24-48 hours.
- MDMA treatment decreased BDNF mRNA expression (up to 73%) in the hippocampus 2-7 days post-treatment, despite increased phospho-CREB.
- Differential regulation of BDNF in the frontal cortex and hippocampus was observed.
Conclusions:
- Increased BDNF expression in the frontal cortex contributes to enhanced TPH expression and 5-HT recovery.
- Decreased BDNF expression in the hippocampus may hinder 5-HT recovery, potentially due to corticosterone release.
- BDNF plays a critical role in the region-specific neuroadaptive responses to MDMA.
More Related Videos
05:17BS3 Chemical Crosslinking Assay: Evaluating the Effect of Chronic Stress on Cell Surface GABAA Receptor Presentation in the Rodent Brain
Published on: May 26, 2023
09:16A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016